CATB:NSD-Catabasis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.72

Change

+0.05 (+2.99)%

Market Cap

USD 0.13B

Volume

0.25M

Avg Analyst Target

USD 5.50 (+219.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Company Website : http://www.catabasis.com

Address : 100 High Street, Boston, MA, United States, 02110

Employees : 20

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.65

52 Week High : 8.59

Short Ratio : 0.85

52 Week Low : 1.25

Shorted Shares : 2,070,807

200 Day Moving Average : 2.50

Shorted Shares Previous Month : 2,650,804

50 Day Moving Average : 1.98

Shares Held By Insiders : 0.03%

Short Percentage : 3.00%

Shares Held by Institutions : 31.6%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+20.82 (+6.34%)

 USD131.90B 220.17 184.41
BNTX BioNTech SE

+29.45 (+10.37%)

 USD68.59B 51.85 43.53
REGN Regeneron Pharmaceuticals, Inc

+5.40 (+0.93%)

 USD61.90B 16.54 12.91
VRTX Vertex Pharmaceuticals Incorpo..

-0.61 (-0.30%)

 USD52.51B 19.34 13.17
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.69 (+1.57%)

 USD28.97B 32.86 3.81
BGNE BeiGene, Ltd

+43.46 (+16.14%)

 USD27.52B N/A N/A
SGEN Seagen Inc

+1.68 (+1.16%)

 USD26.21B 40.30 35.56
RPRX Royalty Pharma plc

-0.67 (-1.71%)

 USD23.80B 32.32 14.58
ALNY Alnylam Pharmaceuticals, Inc

+5.51 (+3.12%)

 USD20.76B N/A N/A

ETFs Containing CATB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.63% 41% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.63% 41% F 17% F
Trailing 12 Months  
Capital Gain -71.24% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.24% 4% F 2% F
Trailing 5 Years  
Capital Gain -95.56% 9% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.56% 9% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -32.98% 5% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.98% 5% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 33.91% 81% B- 53% F
Risk Adjusted Return -97.27% 3% F 1% F
Market Capitalization 0.13B 26% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.02 95% A 87% B+
Price / Cash Flow Ratio -3.96 33% F 63% D
EV/EBITDA 0.59 55% F 92% A-
Management Effectiveness  
Return on Equity -206.19% 10% F 14% F
Return on Invested Capital -98.01% 19% F 7% F
Return on Assets -20.60% 58% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.85 84% B 76% C
Short Percent 13.16% 15% F 13% F
Beta 1.65 34% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.